Navigation Links
HeartWare Receives Conditional Approval From FDA to Enroll Supplemental Patient Cohort in Destination Therapy Trial
Date:6/17/2013

FRAMINGHAM, Mass., and SYDNEY, June 17, 2013 /PRNewswire/ -- HeartWare International, Inc. (Nasdaq: HTWR; ASX: HIN), a leading innovator of less invasive, miniaturized circulatory support technologies that are revolutionizing the treatment of advanced heart failure, today announced that the U.S. Food and Drug Administration (FDA) has granted conditional approval to an IDE (Investigational Device Exemption) Supplement that allows HeartWare to commence enrollment in an additional patient cohort for ENDURANCE, the Company's pivotal, Destination Therapy clinical study.

ENDURANCE is a randomized, controlled, unblinded, multi-center clinical trial to evaluate the use of the HeartWare® Ventricular Assist System as a Destination Therapy in advanced heart failure patients.  The non-inferiority study completed enrollment of 450 patients with end-stage heart failure who had not responded to standard medical management and who were ineligible for cardiac transplantation.  Patients were randomly selected to receive either the HeartWare Ventricular Assist System or, as part of a control group, any alternative LVAD approved by the FDA for Destination Therapy, in a 2:1 ratio.

The primary endpoint of the trial is stroke-free (Modified Rankin Score > 4) survival at two years, defined as alive on the originally implanted device, transplanted or explanted due to patient recovery. Secondary endpoints include adverse events such as bleeding and infection, as well as functional status, hospitalization, assessment of neuro-cognitive function and patient quality of life.  The final implant was conducted in May 2012, which will result in the final patient reaching the two-year follow up point in May 2014.

Supplemental Patient Cohort

FDA granted conditional approval to a protocol desi
'/>"/>

SOURCE HeartWare International, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. HeartWare Presentation at the Wells Fargo Securities 2013 Healthcare Conference to be Webcast
2. HeartWare International Announces Intention To Delist From Australian Securities Exchange (ASX)
3. HeartWare Presentation At The Goldman Sachs 34th Annual Global Healthcare Conference To Be Webcast
4. HeartWare Presentation At The 2013 UBS Global Healthcare Conference To Be Webcast
5. HeartWare Presentation at the Bank of America Merrill Lynch 2013 Health Care Conference to be Webcast
6. HeartWare International Reports $49.2 Million In First Quarter 2013 Revenue; 87% Increase From First Quarter Of 2012
7. HeartWare Schedules First Quarter Conference Call And Webcast
8. HeartWare International, Inc. Announces Pricing of Public Offering of Common Stock
9. HeartWare International, Inc. Announces Public Offering of Common Stock
10. HeartWare Presentation at the Barclays Capital 2013 Global Healthcare Conference To Be Webcast
11. HeartWare Presentation At Raymond James 34th Annual Institutional Investors Conference To Be Webcast
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2014)... , July 29, 2014 , ... /Oxymorphone clinical development program has commenced , ... during Q4 2014 , TPM®/Oxymorphone ... States in 1H 2015 Australian drug delivery ... its opioid transdermal patch programs after its recent announcement of a ...
(Date:7/29/2014)... July 29, 2014   ... that it has taken an exclusive worldwide licence to ... a Durham University spin-out company. ... pay an upfront fee, development and commercial milestone payments, ... also taken an option for additional exclusive licences to ...
(Date:7/28/2014)... Calif. , July 28, 2014 Pharmacyclics, Inc. ... it will hold a conference call and audio webcast to ... the NASDAQ Market closes on Thursday, July 31, 2014 at ... details: Date: July 31, 2014 Time: ... Toll-free: (877) 303-7908 International: (678) 373-0875 A webcast ...
Breaking Medicine Technology:Phosphagenics Provides Update on Opioid Patch Program 2Phosphagenics Provides Update on Opioid Patch Program 3Phosphagenics Provides Update on Opioid Patch Program 4Phosphagenics Provides Update on Opioid Patch Program 5Phosphagenics Provides Update on Opioid Patch Program 6Glide Pharma Takes Exclusive Worldwide Rights to Novel Diagnostic Technology for Prostate Cancer 2Glide Pharma Takes Exclusive Worldwide Rights to Novel Diagnostic Technology for Prostate Cancer 3Pharmacyclics Announces Date of Conference call to discuss Financial Results for Second Quarter of 2014 2
... Watson Pharmaceuticals, Inc. (NYSE: WPI ), ... Wilkinson , Watson,s Executive Vice President, Global Brands, will provide ... Investment Research Global Healthcare Conference on Wednesday, May 26, ... presentation will be webcast live and can be accessed on ...
... Prometheus Laboratories Inc., a specialty pharmaceutical and diagnostic company, announced a ... infliximab, a biologic therapy that has been used to treat more ... rheumatoid arthritis, Crohn,s disease and ulcerative colitis. , ... Human anti-chimeric antibody (HACA) levels have ...
Cached Medicine Technology:Watson to Present at the 2010 Citi Investment Research Global Healthcare Conference 2Prometheus Announces New Method for Real-Time Monitoring of Patients Treated With Biologic Therapy 2
(Date:7/29/2014)... 29, 2014 PeopleKeys today announced that ... teach students how to train and certify others in ... Behavioral Consultant Trainer , will be taught by PeopleKeys ... Training John Schindell as a live Tele-course over the ... The Certified Behavioral Consultant Trainer course will use a ...
(Date:7/29/2014)... In today’s world, a good night’s sleep has ... sleep apnea (a medical problem where the airway collapses during ... of the rest they need to face their daily challenges. ... 20 million people in the United States alone have sleep ... and of those treated, many cannot tolerate their prescribed medical ...
(Date:7/29/2014)... (PRWEB) July 29, 2014 In its ... offers treatment programs and believes that having family close ... big difference in whether or not the process is ... myths. , “It’s difficult to estimate just how damaging ... Rehabilitation’s CEO Per Wickstrom . “Not only do ...
(Date:7/29/2014)... 2014 Nuanced Media, a leading digital ... HIPAA (Health Insurance Portability and Accountability Act) certified firm. ... storage and transfer of Personal Health Information (PHI). ... Nuanced Media can effectively serve their medical industry clients. ... to offer medical industry specific products such as ...
(Date:7/29/2014)... brides want their bridal dresses and bridal parties to ... sure to provide designs of wedding gowns and bridesmaids ... has recently announced its new collection of gorgeous lace ... come with big savings, up to 61% off. , ... working in the garment industry for several years; they ...
Breaking Medicine News(10 mins):Health News:PeopleKeys Announces New Certified Behavioral Consultant Trainer Course 2Health News:PeopleKeys Announces New Certified Behavioral Consultant Trainer Course 3Health News:Snoring: Bad for Relationships, Bad for Health 2Health News:Snoring: Bad for Relationships, Bad for Health 3Health News:Latest Best Drug Rehabilitation Blog Post Busts 4 Big Addiction Myths 2Health News:Latest Best Drug Rehabilitation Blog Post Busts 4 Big Addiction Myths 3Health News:Nuanced Media Web Design Agency Now Hipaa Certified 2Health News:LunaDress’ Summer Sale Has Arrived: All Its Gorgeous Lace Wedding Dresses are Affordable Now 2
... Epidemiologists have long warned that, in addition to causing ... person at greater risk for colon cancer. Now, researchers ... explain why. The findings, "Epigenetic Differences in Normal ... Pathways," were published in the March issue of the ...
... HIV-positive patient, one of her first questions is whether he ... response is about dead relatives or friends. "We talk about ... experience will be very different," said the infectious-disease specialist at ... "Yes it,s the same virus and could have the same ...
... Researchers from Boston University School of Medicine (BUSM) and ... breast pain who receive imaging (mammograms, MRIs or ultrasounds) ... testing, but do not gain benefit from these additional ... of General Internal Medicine. Breast pain is ...
... -- Exposure to cocaine, tobacco or marijuana before birth ... tests, according to a new study. Prenatal alcohol ... fetal alcohol syndrome, was associated with lower scores at ... researchers found. The negative associations between intrauterine alcohol ...
... Reporter , TUESDAY, March 6 (HealthDay News) -- New research ... longevity in humans by showing that genetically modified mice live ... a few differences between mice and humans, especially in regard ... genetic tweak, so there,s no way to know if the ...
... -- When faced with stressful situations, older adults who sleep ... a new study finds. The marker, called interleukin-6 (IL-6), ... as cardiovascular disease, diabetes and psychiatric problems. "Our study ... sleep and what poor sleep may be doing to our ...
Cached Medicine News:Health News:Study shows how high-fat diets increase colon cancer risk 2Health News:Federal grant enables HIV testing, treatment in the Augusta area 2Health News:Federal grant enables HIV testing, treatment in the Augusta area 3Health News:Research finds little benefit of breast imaging tests for women with breast pain 2Health News:Fetal Cocaine Exposure May Not Affect Kids' Academics: Study 2Health News:Genetic Tweak Helps Mice Avoid Cancer, Obesity: Study 2Health News:Poor Sleep May Impact Stress Response in Older Adults 2
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
Medicine Products: